SEARCH:   Advanced

Blood, 1 April 2006, Vol. 107, No. 7, pp. 2639-2642. Prepublished online as a Blood First Edition Paper on December 13, 2005; DOI 10.1182/blood-2005-08-3518. This Article Full Text (PDF) Supplemental Data All Versions of this Article: 2005-08-3518v1 107/7/2639    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bennett, C. M Articles by , Search for Related Content PubMed PubMed Citation Articles by Bennett, C. M Articles by , Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 31, 2005 Accepted November 22, 2005 Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura Carolyn M Bennett, Zora R Rogers, Daniel D Kinnamon, James B Bussel, Donald H Mahoney, Thomas C Abshire, Hadi Sawaf, Theodore B Moore, Mignon L Loh, Bertil E Glader, Maggie C McCarthy, Brigitta U Mueller, Thomas A Olson, Adonis N Lorenzana, William C Mentzer, George R Buchanan, Henry A Feldman, Ellis J Neufeld*, and Division of Hematology/Oncology, Children's Hospital Boston, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA University of Texas, Southwestern Medical Center, Dallas, TX, USA Clinical Research Program, Children's Hospital Boston, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA Weill Medical College at Cornell University, New York, NY, USA Baylor College of Medicine, Houston, TX, USA Emory University School of Medicine, Atlanta, GA, USA Van Eslander Cancer Center, St. John Hospital, Detroit, MI, USA University of California, Los Angeles/Mattel Children's Hospital at UCLA, Los Angeles, CA, USA University of California, San Francisco, CA, USA Stanford University, Stanford, CA, USA * Corresponding author; email: ellis.neufeld{at}childrens.harvard.edu. We assessed safety and efficacy of rituximab in a prospective study of 36 patients, age 2.6-18.3 years, with severe chronic immune thrombocytopenic purpura (ITP). The primary outcome of sustained platelets > 50,000/mm3 during four consecutive weeks, starting in weeks 9 to12, was achieved by 11 of 36 patients (31%, CI 16-48%). Median response time was one week (range 1-7). Attainment of the primary outcome was not associated with age, prior pharmacologic responses, prior splenectomy, ITP duration, screening platelet count, refractoriness or IgM reduction. First dose, infusion-related toxicity was common (47%) despite premedication. Significant drug related toxicities included third-dose hypotension (n=1) and serum sickness (n=2). Peripheral B cells were depleted in all subjects. IgM decreased 3.4% per wk, but IgG did not significantly decrease. Rituximab was well tolerated, with manageable infusion-related side effects, but 6% of subjects developed serum sickness. Rituximab is beneficial for some pediatric patients with severe, chronic ITP. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Putting the "Tux" on ITP Douglas B. Cines Blood 2006 107: 2590-2591. [Full Text] [PDF] This article has been cited by other articles: D Albert, J Dunham, S Khan, J Stansberry, S Kolasinski, D Tsai, S Pullman-Mooar, F Barnack, C Striebich, R J Looney, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus Ann Rheum Dis, December 1, 2008; 67(12): 1724 - 1731. [Abstract] [Full Text] [PDF] C. E. Neunert, G. R. Buchanan, P. Imbach, P. H. B. Bolton-Maggs, C. M. Bennett, E. J. Neufeld, S. K. Vesely, L. Adix, V. S. Blanchette, T. Kuhne, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura Blood, November 15, 2008; 112(10): 4003 - 4008. [Abstract] [Full Text] [PDF] S. Berentsen Rituximab for the treatment of autoimmune cytopenias Haematologica, December 1, 2007; 92(12): 1589 - 1596. [Full Text] [PDF] B. Bader-Meunier, N. Aladjidi, F. Bellmann, F. Monpoux, B. Nelken, A. Robert, C. Armari-Alla, C. Picard, F. Ledeist, M. Munzer, et al. Rituximab therapy for childhood Evans syndrome Haematologica, December 1, 2007; 92(12): 1691 - 1694. [Abstract] [Full Text] [PDF] C. G. Brunstein, D. J. Weisdorf, T. DeFor, J. N. Barker, J. Tolar, J.-A. H. van Burik, and J. E. Wagner Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation Blood, October 15, 2006; 108(8): 2874 - 2880. [Abstract] [Full Text] [PDF] D. J. Nugent Immune Thrombocytopenic Purpura of Childhood Hematology, January 1, 2006; 2006(1): 97 - 103. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020